{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:07:10Z","timestamp":1785856030309,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","award":["Heart-Brain Connection BHRIITE IMPACT Award"],"award-info":[{"award-number":["Heart-Brain Connection BHRIITE IMPACT Award"]}],"id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009408","name":"Fondation Brain Canada","doi-asserted-by":"publisher","award":["Heart-Brain Connection BHRIITE IMPACT Award"],"award-info":[{"award-number":["Heart-Brain Connection BHRIITE IMPACT Award"]}],"id":[{"id":"10.13039\/100009408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["202111FBD-47623-75801"],"award-info":[{"award-number":["202111FBD-47623-75801"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010785","name":"Canada First Research Excellence Fund","doi-asserted-by":"publisher","award":["Heart-Brain Connection BHRIITE IMPACT Award"],"award-info":[{"award-number":["Heart-Brain Connection BHRIITE IMPACT Award"]}],"id":[{"id":"10.13039\/501100010785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00125-025-06595-0","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T09:24:10Z","timestamp":1762593850000},"page":"386-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiovascular effectiveness and safety of SGLT2 inhibitors vs DPP4 inhibitors by dementia status: a cohort study of older adults with diabetes"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8548-1824","authenticated-orcid":false,"given":"Che-Yuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi D.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira K.","family":"Kapral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Fangyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Podolsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0030-8908","authenticated-orcid":false,"given":"Walter","family":"Swardfager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3598-3628","authenticated-orcid":false,"given":"Baiju R.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"issue":"4","key":"6595_CR1","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2337\/ds16-0035","volume":"29","author":"R Hopkins","year":"2016","unstructured":"Hopkins R, Shaver K, Weinstock RS (2016) Management of adults with diabetes and cognitive problems. Diabetes Spectr 29(4):224\u2013237. https:\/\/doi.org\/10.2337\/ds16-0035","journal-title":"Diabetes Spectr"},{"issue":"Suppl 1","key":"6595_CR2","doi-asserted-by":"publisher","first-page":"S283","DOI":"10.1016\/j.jcjd.2017.10.021","volume":"42","author":"GS Meneilly","year":"2018","unstructured":"Meneilly GS, Knip A, Miller DB, Sherifali D, Tessier D, Zahedi A (2018) Diabetes in older people. Can J diabetes 42(Suppl 1):S283\u2013S295. https:\/\/doi.org\/10.1016\/j.jcjd.2017.10.021","journal-title":"Can J diabetes"},{"issue":"Suppl 1","key":"6595_CR3","doi-asserted-by":"publisher","first-page":"S244","DOI":"10.2337\/dc24-S013","volume":"47","author":"ADA Professional Practice Committee","year":"2024","unstructured":"ADA Professional Practice Committee (2024) 13. Older adults: standards of care in diabetes-2024. Diabetes Care 47(Suppl 1):S244\u2013S257. https:\/\/doi.org\/10.2337\/dc24-S013","journal-title":"Diabetes Care"},{"issue":"7","key":"6595_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jcjd.2024.08.002","volume":"48","author":"BR Shah","year":"2024","unstructured":"Shah BR, Bajaj HS, Butalia S et al (2024) Pharmacologic glycemic management of type 2 diabetes in adults---2024 Update. Can J Diabetes 48(7):415\u2013424. https:\/\/doi.org\/10.1016\/j.jcjd.2024.08.002","journal-title":"Can J Diabetes"},{"issue":"Suppl 1","key":"6595_CR5","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc24-S009","volume":"47","author":"ADA Professional Practice Committee","year":"2024","unstructured":"ADA Professional Practice Committee (2024) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care 47(Suppl 1):S158\u2013S178. https:\/\/doi.org\/10.2337\/dc24-S009","journal-title":"Diabetes Care"},{"issue":"2","key":"6595_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F et al (2021) Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 6(2):148\u2013158. https:\/\/doi.org\/10.1001\/jamacardio.2020.4511","journal-title":"JAMA Cardiol"},{"issue":"10365","key":"6595_CR7","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400(10365):1788\u20131801. https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8","journal-title":"Lancet"},{"issue":"2","key":"6595_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2337\/dc22-1705","volume":"46","author":"C-Y Wu","year":"2023","unstructured":"Wu C-Y, Iskander C, Wang C et al (2023) Association of sodium\u2013glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study. Diabetes Care 46(2):297\u2013304. https:\/\/doi.org\/10.2337\/dc22-1705","journal-title":"Diabetes Care"},{"key":"6595_CR9","doi-asserted-by":"publisher","first-page":"e079475","DOI":"10.1136\/bmj-2024-079475","volume":"386","author":"A Shin","year":"2024","unstructured":"Shin A, Koo BK, Lee JY, Kang EH (2024) Risk of dementia after initiation of sodium\u2013glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40\u201369 years with type 2 diabetes: population based cohort study. BMJ 386:e079475. https:\/\/doi.org\/10.1136\/bmj-2024-079475","journal-title":"BMJ"},{"key":"6595_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0353","author":"H Tang","year":"2025","unstructured":"Tang H, Donahoo WT, DeKosky ST et al (2025) GLP-1RA and SGLT2i medications for type 2 diabetes and Alzheimer disease and related dementias. JAMA Neurol https:\/\/doi.org\/10.1001\/jamaneurol.2025.0353","journal-title":"JAMA Neurol"},{"issue":"11","key":"6595_CR11","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.2337\/dc23-0671","volume":"46","author":"A Kutz","year":"2023","unstructured":"Kutz A, Kim DH, Wexler DJ et al (2023) Comparative cardiovascular effectiveness and safety of SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors according to frailty in type 2 diabetes. Diabetes Care 46(11):2004\u20132014. https:\/\/doi.org\/10.2337\/dc23-0671","journal-title":"Diabetes Care"},{"issue":"4","key":"6595_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund JL, Richardson DB, St\u00fcrmer T (2015) The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep 2(4):221\u2013228. https:\/\/doi.org\/10.1007\/s40471-015-0053-5","journal-title":"Curr Epidemiol Rep"},{"issue":"7","key":"6595_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","volume":"11","author":"K Yoshida","year":"2015","unstructured":"Yoshida K, Solomon DH, Kim SC (2015) Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol 11(7):437\u2013441. https:\/\/doi.org\/10.1038\/nrrheum.2015.30","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"6595_CR14","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM (2016) Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol 183(8):758\u2013764. https:\/\/doi.org\/10.1093\/aje\/kwv254","journal-title":"Am J Epidemiol"},{"key":"6595_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","volume":"79","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Sauer BC, Hern\u00e1ndez-D\u00edaz S, Platt R, Shrier I (2016) Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol 79:70\u201375. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.04.014","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"6595_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12913-018-3148-0","volume":"18","author":"LL Lipscombe","year":"2018","unstructured":"Lipscombe LL, Hwee J, Webster L, Shah BR, Booth GL, Tu K (2018) Identifying diabetes cases from administrative data: a population-based validation study. BMC Health Serv Res 18(1):316. https:\/\/doi.org\/10.1186\/s12913-018-3148-0","journal-title":"BMC Health Serv Res"},{"key":"6595_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JAD-160105","volume":"54","author":"RL Jaakkimainen","year":"2016","unstructured":"Jaakkimainen RL, Bronskill SE, Tierney MC et al (2016) Identification of physician-diagnosed Alzheimer\u2019s disease and related dementias in population-based administrative data: a validation study using family physicians\u2019 electronic medical records. J Alzheimer\u2019s Dis 54:337\u2013349. https:\/\/doi.org\/10.3233\/JAD-160105","journal-title":"J Alzheimer\u2019s Dis"},{"key":"6595_CR18","doi-asserted-by":"publisher","first-page":"m3342","DOI":"10.1136\/bmj.m3342","volume":"370","author":"KB Filion","year":"2020","unstructured":"Filion KB, Lix LM, Yu OH et al (2020) Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ 370:m3342. https:\/\/doi.org\/10.1136\/bmj.m3342","journal-title":"BMJ"},{"issue":"2","key":"6595_CR19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1067\/mhj.2002.123839","volume":"144","author":"PC Austin","year":"2002","unstructured":"Austin PC, Daly PA, Tu JV (2002) A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J 144(2):290\u2013296. https:\/\/doi.org\/10.1067\/mhj.2002.123839","journal-title":"Am Heart J"},{"issue":"6","key":"6595_CR20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1017\/cjn.2016.278","volume":"43","author":"R Hall","year":"2016","unstructured":"Hall R, Mondor L, Porter J, Fang J, Kapral MK (2016) Accuracy of administrative data for the coding of acute stroke and TIAs. Can J Neurol Sci 43(6):765\u2013773. https:\/\/doi.org\/10.1017\/cjn.2016.278","journal-title":"Can J Neurol Sci"},{"issue":"6","key":"6595_CR21","doi-asserted-by":"publisher","first-page":"e001821","DOI":"10.1136\/bmjopen-2012-001821","volume":"2","author":"YJ Hwang","year":"2012","unstructured":"Hwang YJ, Shariff SZ, Gandhi S et al (2012) Validity of the International Classification of Diseases, Tenth Revision code for acute kidney injury in elderly patients at presentation to the emergency department and at hospital admission. BMJ Open 2(6):e001821. https:\/\/doi.org\/10.1136\/bmjopen-2012-001821","journal-title":"BMJ Open"},{"issue":"4","key":"6595_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jcjd.2024.01.006","volume":"48","author":"B Hodzic-Santor","year":"2024","unstructured":"Hodzic-Santor B, Colacci M, Raissi A et al (2024) Validation of the diagnostic accuracy levels of international classification of diseases, 10th revision codes for diabetic ketoacidosis: a multicentre, cross-sectional study of adults. Can J Diabetes 48(4):227\u2013232. https:\/\/doi.org\/10.1016\/j.jcjd.2024.01.006","journal-title":"Can J Diabetes"},{"issue":"3","key":"6595_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jcjd.2016.11.003","volume":"41","author":"MC Hodge","year":"2017","unstructured":"Hodge MC, Dixon S, Garg AX, Clemens KK (2017) Validation of an international statistical classification of diseases and related health problems 10th revision coding algorithm for hospital encounters with hypoglycemia. Can J Diabetes 41(3):322\u2013328. https:\/\/doi.org\/10.1016\/j.jcjd.2016.11.003","journal-title":"Can J Diabetes"},{"issue":"3","key":"6595_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1503\/cmaj.100702","volume":"183","author":"AJ Wright","year":"2011","unstructured":"Wright AJ, Gomes T, Mamdani MM, Horn JR, Juurlink DN (2011) The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. CMAJ 183(3):303\u2013307. https:\/\/doi.org\/10.1503\/cmaj.100702","journal-title":"CMAJ"},{"issue":"25","key":"6595_CR25","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28(25):3083\u20133107. https:\/\/doi.org\/10.1002\/sim.3697","journal-title":"Stat Med"},{"issue":"6","key":"6595_CR26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","volume":"133","author":"PC Austin","year":"2016","unstructured":"Austin PC, Lee DS, Fine JP (2016) Introduction to the analysis of survival data in the presence of competing risks. Circulation 133(6):601\u2013609. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.017719","journal-title":"Circulation"},{"issue":"6","key":"6595_CR27","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1053\/j.ajkd.2021.09.015","volume":"79","author":"M Zhuo","year":"2022","unstructured":"Zhuo M, Paik JM, Wexler DJ, Bonventre JV, Kim SC, Patorno E (2022) SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes. Am J Kidney Dis 79(6):858-867.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2021.09.015","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"6595_CR28","doi-asserted-by":"publisher","first-page":"e002496","DOI":"10.1136\/bmjdrc-2021-002496","volume":"9","author":"W Alkabbani","year":"2021","unstructured":"Alkabbani W, Zongo A, Minhas-Sandhu JK et al (2021) Renal effectiveness and safety of the sodium\u2013glucose cotransporter-2 inhibitors: a population-based cohort study. BMJ Open Diabetes Res Care 9(2):e002496. https:\/\/doi.org\/10.1136\/bmjdrc-2021-002496","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"14","key":"6595_CR29","doi-asserted-by":"publisher","first-page":"E351","DOI":"10.1503\/cmaj.191283","volume":"192","author":"C Iskander","year":"2020","unstructured":"Iskander C, Cherney DZ, Clemens KK et al (2020) Use of sodium\u2013glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study. CMAJ 192(14):E351\u2013E360. https:\/\/doi.org\/10.1503\/cmaj.191283","journal-title":"CMAJ"},{"key":"6595_CR30","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstr\u00f6m H, Melbye M et al (2018) Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 363:k4365. https:\/\/doi.org\/10.1136\/bmj.k4365","journal-title":"BMJ"},{"issue":"7","key":"6595_CR31","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1007\/s00125-024-06126-3","volume":"67","author":"PT Htoo","year":"2024","unstructured":"Htoo PT, Tesfaye H, Schneeweiss S et al (2024) Effectiveness and safety of empagliflozin: final results from the EMPRISE study. Diabetologia 67(7):1328\u20131342. https:\/\/doi.org\/10.1007\/s00125-024-06126-3","journal-title":"Diabetologia"},{"issue":"2","key":"6595_CR32","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/dom.13531","volume":"21","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Patorno E (2019) Comparative risk of genital infections associated with sodium\u2013glucose co-transporter-2 inhibitors. Diabetes Obes Metab 21(2):434\u2013438. https:\/\/doi.org\/10.1111\/dom.13531","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"6595_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","volume":"55","author":"R Puckrin","year":"2018","unstructured":"Puckrin R, Saltiel M-P, Reynier P, Azoulay L, Yu OHY, Filion KB (2018) SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 55(5):503\u2013514. https:\/\/doi.org\/10.1007\/s00592-018-1116-0","journal-title":"Acta Diabetol"},{"issue":"8","key":"6595_CR34","doi-asserted-by":"publisher","first-page":"e14858","DOI":"10.1111\/dme.14858","volume":"39","author":"W Alkabbani","year":"2022","unstructured":"Alkabbani W, Zongo A, Minhas-Sandhu JK et al (2022) Five comparative cohorts to assess the risk of genital tract infections associated with sodium\u2013glucose cotransporter-2 inhibitors initiation in type 2 diabetes mellitus. Diabet Med 39(8):e14858. https:\/\/doi.org\/10.1111\/dme.14858","journal-title":"Diabet Med"},{"issue":"6","key":"6595_CR35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7326\/M20-0289","volume":"173","author":"A Douros","year":"2020","unstructured":"Douros A, Lix LM, Fralick M et al (2020) Sodium\u2013glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Intern Med 173(6):417\u2013425. https:\/\/doi.org\/10.7326\/M20-0289","journal-title":"Ann Intern Med"},{"issue":"1","key":"6595_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jcjd.2021.04.006","volume":"46","author":"M Colacci","year":"2022","unstructured":"Colacci M, Fralick J, Odutayo A, Fralick M (2022) Sodium\u2013glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta-analysis. Can J Diabetes 46(1):10-15.e2. https:\/\/doi.org\/10.1016\/j.jcjd.2021.04.006","journal-title":"Can J Diabetes"},{"issue":"11","key":"6595_CR37","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1111\/dom.13820","volume":"21","author":"IC Lega","year":"2019","unstructured":"Lega IC, Bronskill SE, Campitelli MA et al (2019) Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes. Diabetes Obes Metab 21(11):2394\u20132404. https:\/\/doi.org\/10.1111\/dom.13820","journal-title":"Diabetes Obes Metab"},{"key":"6595_CR38","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1056\/NEJMc1701990","volume":"376","author":"M Fralick","year":"2017","unstructured":"Fralick M, Schneeweiss S, Patorno E (2017) Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 376:2300\u20132302. https:\/\/doi.org\/10.1056\/NEJMc1701990","journal-title":"N Engl J Med"},{"issue":"4","key":"6595_CR39","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/dom.14300","volume":"23","author":"M Fralick","year":"2021","unstructured":"Fralick M, Colacci M, Thiruchelvam D, Gomes T, Redelmeier DA (2021) Sodium\u2013glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a nationwide cohort study of older adults with diabetes mellitus. Diabetes Obes Metab 23(4):950\u2013960. https:\/\/doi.org\/10.1111\/dom.14300","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"6595_CR40","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1007\/s11606-020-06561-z","volume":"36","author":"M Fralick","year":"2021","unstructured":"Fralick M, Redelmeier DA, Patorno E et al (2021) Identifying risk factors for diabetic ketoacidosis associated with SGLT2 inhibitors: a nationwide cohort study in the USA. J Gen Intern Med 36(9):2601\u20132607. https:\/\/doi.org\/10.1007\/s11606-020-06561-z","journal-title":"J Gen Intern Med"},{"issue":"5","key":"6595_CR41","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S2213-8587(20)30042-5","volume":"8","author":"D Ehrmann","year":"2020","unstructured":"Ehrmann D, Kulzer B, Roos T, Haak T, Al-Khatib M, Hermanns N (2020) Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes. Lancet Diabetes Endocrinol 8(5):436\u2013446. https:\/\/doi.org\/10.1016\/S2213-8587(20)30042-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"6595_CR42","doi-asserted-by":"publisher","first-page":"820","DOI":"10.7326\/M21-4776","volume":"175","author":"JH Butt","year":"2022","unstructured":"Butt JH, Dewan P, Merkely B et al (2022) Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF Trial. Ann Intern Med 175(6):820\u2013830. https:\/\/doi.org\/10.7326\/M21-4776","journal-title":"Ann Intern Med"},{"issue":"16","key":"6595_CR43","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.122.061754","volume":"146","author":"JH Butt","year":"2022","unstructured":"Butt JH, Jhund PS, Belohl\u00e1vek J et al (2022) Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation 146(16):1210\u20131224. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061754","journal-title":"Circulation"},{"issue":"1","key":"6595_CR44","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/jcsm.13393","volume":"15","author":"AJS Coats","year":"2024","unstructured":"Coats AJS, Butler J, Tsutsui H et al (2024) Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved. J Cachexia Sarcopenia Muscle 15(1):412\u2013424. https:\/\/doi.org\/10.1002\/jcsm.13393","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"5","key":"6595_CR45","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2337\/dc21-2434","volume":"45","author":"P Mone","year":"2022","unstructured":"Mone P, Lombardi A, Gambardella J et al (2022) Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction. Diabetes Care 45(5):1247\u20131251. https:\/\/doi.org\/10.2337\/dc21-2434","journal-title":"Diabetes Care"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06595-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-025-06595-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06595-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:03:11Z","timestamp":1767823391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-025-06595-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["6595"],"URL":"https:\/\/doi.org\/10.1007\/s00125-025-06595-0","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,8]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ICES is an independent, non-profit research institute funded by an annual grant from the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). As a prescribed entity under Ontario\u2019s privacy legislation, ICES is authorised to collect and use healthcare data for the purposes of health system analysis, evaluation and decision support. Secure access to these data is governed by policies and procedures that are approved by the Information and Privacy Commissioner of Ontario.\u00a0This document used data adapted from the Statistics Canada Postal Code\n                      OM\n                      Conversion File, which is based on data licensed from Canada Post Corporation, and\/or data adapted from the Ontario Ministry of Health Postal Code Conversion File, which contains data copied under license from\n                      \u00a9\n                      Canada Post Corporation and Statistics Canada. Parts of this material are based on data and\/or information compiled and provided by the Ontario Ministry of Health and Canadian Institute for Health Information (CIHI). The analyses, conclusions, opinions and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources; no endorsement is intended or should be inferred. We thank IQVIA Solutions Canada Inc. for use of their Drug Information File.This Project has been made possible by the Canada Brain Research Fund (CBRF), an innovative arrangement between the Government of Canada (through Health Canada) and Brain Canada Foundation, and Heart and Stroke Foundation of Canada. To date, Health Canada has invested over $130 million through the CBRF which has been matched by Brain Canada Foundation and its donors and partners. The views expressed herein do not necessarily represent the views of the Minister of Health or the Government of Canada.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"The dataset from this study is held securely in coded form at ICES (formerly, Institute for Clinical Evaluative Sciences). While data sharing agreements prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at\n                      \n                      . The full dataset creation plan and underlying analytic code are available from the authors upon request, on the understanding that the computer programs may rely upon coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"CYW receives financial support from the Canadian Institutes of Health Research (Doctoral Research Award: Canadian Graduate Scholarships; 202111FBD-47623-75801). CYW, WS, AS, JDE and PPL receive financial support from Heart-Brain Connection BHRIITE IMPACT Award from Heart & Stroke Foundation, Brain Canada, and the Brain-Heart Interconnectome CFREF (Canada First Research Excellence Fund) Program.\u00a0BRS receives support from the University of Toronto as the Novo Nordisk Research Chair in Equitable Care of Diabetes and Related Conditions.\u00a0WS receives support from the Canada Research Chairs Program (Award Number: CRC-2020-00353), the Ontario Ministry of Colleges and Universities (Award Number: ER21-16-141), the Alzheimer\u2019s Drug Discovery Foundation (Grant Number: GC-202209-2024050), and the Dr. Sandra Black Centre for Brain Resilience and Recovery.\u00a0AS acknowledges financial support from the FRQS-Junior 1\/2 clinician scientist award, the Alberta Innovates Health Solution Clinician Scientist fellowship, the European Society of Cardiology Young Investigator research grant, Janssen, Roche Diagnostics, AstraZeneca, Boehringer Ingelheim, Novartis, Servier, Novo Nordisk, Takeda, and the Canadian Cardiovascular Society Bayer Vascular award.\u00a0MKK is supported by the Sir John and Lady Eaton Chair from the Department of Medicine, Temerty Faculty of Medicine, University of Toronto.\u00a0All funders for the present project and other unrelated projects did not influence the conduct, interpretation, and reporting of the present study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"CYW, WS and BRS conceptualised the study. CYW, AS, JDE, CFW, BRS and WS made significant contributions to the study design and methodology. CYW, CFW and SP made significant contributions to the data analysis. CYW ran the formal analysis and drafted the manuscript. WS and BRS played a supervisory role for this study. AS, JDE, PPL and WS acquired the funding. All authors had significant input into the interpretation of the results and the review or editing of the manuscript, and had approved the final version for publication. CYW, WS and BRS are the guarantors of this work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}